Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Æterna Zentaris Stories

2012-09-25 02:27:46

QUEBEC CITY, Sept. 25, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the European Patent Office ("EPO") has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency ("GHD") in a human or animal subject. Filed on February 19, 2007, the patent (EP #1 984 744 B1) titled, "Methods and Kits to Diagnose Growth...

2012-09-20 02:28:29

QUEBEC CITY, Sept. 20, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster on its oral prostate cancer vaccine candidate, AEZS-120, will be on display at the upcoming 32(nd) Congress of the Société Internationale d'Urologie which will be held September 30 through October 4, 2012 at the Fukuoka International Congress Center in Fukuoka, Japan. The abstract #839 titled, "Pre-Clinical Proof of...

2012-09-05 02:31:42

QUÉBEC CITY, Sept. 5, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its President and CEO, Juergen Engel, PhD, will be presenting a corporate overview at the Rodman & Renshaw 14(th) Annual Global Investment Conference on Tuesday, September 11, 2012, at 1:35 pm (Eastern), in the Starlight North Room of The Waldorf=Astoria Hotel in New York. A live webcast of this presentation will be available on...

2012-08-29 02:25:08

QUÉBEC CITY, Aug. 29, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, MD, will be presenting a corporate overview at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5, 2012, at 11:30 am (Eastern), in the Winthrop Room of the Four Seasons Hotel in Boston. A live webcast of this presentation will be available on Aeterna...

2012-08-28 02:28:10

QUÉBEC CITY, Aug. 28, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia. The study is conducted under a Cooperative Research and Development Agreement (CRADA) between Aeterna Zentaris and the Michael E. DeBakey Veterans Affairs Medical Center which is funding the study. Cachexia,...

2012-08-14 10:25:00

All amounts are in U.S. dollars QUEBEC CITY, Aug. 14, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today reported financial and operating results as at and for the second quarter ended June 30, 2012. Highlights Perifosine (Oral Akt Inhibitor) -- Phase 3 results for perifosine in refractory colorectal cancer presented at ASCO in Chicago. Data showed no benefit in overall survival and in...

2012-08-13 02:25:36

QUÉBEC CITY, Aug. 13, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its V.P., Medicinal Chemistry, Matthias Gerlach, PhD, will be making a poster presentation on preclinical results for the Company's novel orally active anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, during the 244(th) National Meeting of the American Chemistry Society which will be held August 19-23, 2012, in Philadelphia....

2012-08-08 02:27:39

QUEBEC CITY, Aug. 8, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its second quarter 2012 financial and operating results after market close on Tuesday, August 14, 2012. The Company will host a conference call on the following day, Wednesday, August 15, 2012, at 8:30 a.m. (Eastern Time), to discuss these results, provide an update on the Company's business and discuss expectations for the future. Participants may access the...

2012-07-05 02:23:58

QUÉBEC CITY, July 5, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its President and CEO, Juergen Engel, PhD, will be presenting a corporate overview at the 7(th) Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012, at 10:30 am (Eastern), in the Gramercy South Room of the Peninsula Hotel in New York City. A live webcast of this presentation will be available on Aeterna Zentaris'...

2012-06-19 02:27:27

QUÉBEC CITY, June 19, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announces that the Company has learned that two putative class action lawsuits have been filed against it alleging failures to disclose certain information under U.S. federal securities laws. The Company is in the process of reviewing the allegations, believes they are without merit and stands behind its continuous public disclosure record. Aeterna...